Virtus Investment Advisers LLC Has $402,000 Stock Position in Geron Corporation $GERN

Virtus Investment Advisers LLC grew its holdings in shares of Geron Corporation (NASDAQ:GERN) by 211.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 284,868 shares of the biopharmaceutical company’s stock after purchasing an additional 193,281 shares during the quarter. Virtus Investment Advisers LLC’s holdings in Geron were worth $402,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Frisch Financial Group Inc. boosted its position in Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 8,700 shares during the period. StoneCrest Wealth Management Inc. bought a new position in Geron in the 2nd quarter worth $35,000. Savant Capital LLC boosted its holdings in Geron by 73.8% during the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 11,074 shares during the period. Summit Financial Strategies Inc. acquired a new stake in shares of Geron in the second quarter valued at about $38,000. Finally, Focus Partners Advisor Solutions LLC bought a new position in shares of Geron in the first quarter worth about $39,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GERN has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Friday, October 31st. Needham & Company LLC lowered their price objective on shares of Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Geron has an average rating of “Hold” and a consensus target price of $3.64.

Geron Stock Performance

Shares of NASDAQ:GERN opened at $1.18 on Friday. The business’s fifty day moving average price is $1.23 and its two-hundred day moving average price is $1.33. Geron Corporation has a fifty-two week low of $1.04 and a fifty-two week high of $4.20. The stock has a market capitalization of $750.07 million, a price-to-earnings ratio of -9.04 and a beta of 0.57. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The company had revenue of $47.23 million during the quarter, compared to analysts’ expectations of $55.24 million. As a group, analysts predict that Geron Corporation will post -0.25 EPS for the current fiscal year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.